Ian P. Sinha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ian P. Sinha has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Kerry Dwan
Department of Biostatistics, University of Liverpool, Liverpool, UK
2 shared publications Kevin W Southern
University of Liverpool; Department of Women's and Children's Health; Alder Hey Children's Foundation Trust Eaton Road Liverpool Merseyside UK L12 2AP
2 shared publicationsAlex Cleator
1 shared publicationAlice Lee
Department of Women’s and Children’s Health, University of Liverpool, Liverpool, UK
1 shared publication- Atul Gupta
Department of Paediatric Respiratory Medicine, King's College Hospital NHS Foundation Trust, London, UK; Department of Women and Children's Health, Faculty of Life Sciences and Medicine, King's College London, London, UK
1 shared publication Carlos Echevarria
University Hospital of North Tees
1 shared publication
Latest Publications
- Open Access
Treating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial
Introduction A minority of school-aged children with asthma have persistent poor control and experience frequent asthma attacks despite maximal prescribed maintenance therapy. These children have higher morbidity and risk of death. The first add-on biologic therapy, omalizumab, a monoclonal antibody that blocks immunoglobulin (Ig)E, was licensed for children with severe asthma in 2005. While omalizumab is an effective treatment, non-response is common. A second biologic, mepolizumab which blocks interleukin 5 and targets eosinophilic inflammation, was licensed in 2018, but the licence was granted by extrapolation of adult clinical trial data to children. This non-inferiority (NI) trial will determine whether mepolizumab is as efficacious as omalizumab in reducing asthma attacks in children with severe therapy resistant asthma (STRA) and refractory difficult asthma (DA). Methods and analysis This is an ongoing multicentre 1:1 randomised NI open-label trial of mepolizumab and omalizumab. Up to 150 children and young people (CYP) aged 6–17 years with severe asthma will be recruited from specialist paediatric severe asthma centres in the UK. Prior to randomisation, children will be monitored for medication adherence for up to 16 weeks to determine STRA and refractory DA diagnoses. Current prescribing recommendations of serum IgE and blood eosinophils will not influence eligibility or enrolment. The primary outcome is the 52-week asthma attack rate. Bayesian analysis using clinician-elicited prior distributions will be used to calculate the posterior probability that mepolizumab is not inferior to omalizumab. Secondary outcomes include Composite Asthma Severity Index, Paediatric Asthma Quality of Life Questionnaire, lung function measures (forced expiratory volume in one second (FEV1), bronchodilator reversibility), fractional exhaled nitric oxide, Asthma Control Test (ACT), health outcomes EuroQol 5 Dimension (EQ-5D) and optimal serum IgE and blood eosinophil levels that may predict a response to therapy. These outcomes will be analysed in a frequentist framework using longitudinal models. Ethics and dissemination The study has been approved by the South Central—Berkshire Research Ethics Committee REC Number 19/SC/0634 and had Clinical Trials Authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) (EudraCT 2019-004085-17). All parents/legal guardians will give informed consent for their child to participate in the trial, and CYP will give assent to participate. The results will be published in peer-reviewed journals, presented at international conferences and disseminated via our patient and public involvement partners. Trial registration number ISRCTN12109108; EudraCT Number: 2019-004085-17.
Open AccessTreating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial
Introduction A minority of school-aged children with asthma have persistent poor control and experience frequent asthma attacks despite maximal prescribed maintenance therapy. These children have higher morbidity and risk of death. The first add-on biologic therapy, omalizumab, a monoclonal antibody that blocks immunoglobulin (Ig)E, was licensed for children with severe asthma in 2005. While omalizumab is an effective treatment, non-response is common. A second biologic, mepolizumab which blocks interleukin 5 and targets eosinophilic inflammation, was licensed in 2018, but the licence was granted by extrapolation of adult clinical trial data to children. This non-inferiority (NI) trial will determine whether mepolizumab is as efficacious as omalizumab in reducing asthma attacks in children with severe therapy resistant asthma (STRA) and refractory difficult asthma (DA). Methods and analysis This is an ongoing multicentre 1:1 randomised NI open-label trial of mepolizumab and omalizumab. Up to 150 children and young people (CYP) aged 6–17 years with severe asthma will be recruited from specialist paediatric severe asthma centres in the UK. Prior to randomisation, children will be monitored for medication adherence for up to 16 weeks to determine STRA and refractory DA diagnoses. Current prescribing recommendations of serum IgE and blood eosinophils will not influence eligibility or enrolment. The primary outcome is the 52-week asthma attack rate. Bayesian analysis using clinician-elicited prior distributions will be used to calculate the posterior probability that mepolizumab is not inferior to omalizumab. Secondary outcomes include Composite Asthma Severity Index, Paediatric Asthma Quality of Life Questionnaire, lung function measures (forced expiratory volume in one second (FEV1), bronchodilator reversibility), fractional exhaled nitric oxide, Asthma Control Test (ACT), health outcomes EuroQol 5 Dimension (EQ-5D) and optimal serum IgE and blood eosinophil levels that may predict a response to therapy. These outcomes will be analysed in a frequentist framework using longitudinal models. Ethics and dissemination The study has been approved by the South Central—Berkshire Research Ethics Committee REC Number 19/SC/0634 and had Clinical Trials Authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) (EudraCT 2019-004085-17). All parents/legal guardians will give informed consent for their child to participate in the trial, and CYP will give assent to participate. The results will be published in peer-reviewed journals, presented at international conferences and disseminated via our patient and public involvement partners. Trial registration number ISRCTN12109108; EudraCT Number: 2019-004085-17.
- Open Access
- 17 May 2024
- Published by Springer Nature in Pulmonary Therapy
- Vol. 10 (2) , 155-170
The Impact of Malnutrition on the Developing Lung and Long-Term Lung Health: A Narrative Review of Global Literature
Worldwide, over 2 billion children under the age of 5 experience stunting, wasting, or are underweight. Malnutrition contributes to 45% of all deaths in this age group (approximately 3.1 million deaths) [1]. Poverty, food insecurity, suboptimal feeding practices, climate change, and conflict are all contributing factors. Malnutrition causes significant respiratory problems, including increased risk of respiratory infections, impaired lung function, and increased risk of subsequent adult respiratory disease, including asthma, COPD, and lung cancer. Childhood malnutrition not only has serious consequences for children's health but it also has numerous consequences on wellbeing and educational attainment. Childhood malnutrition is a complex and multifaceted problem. However, by understanding and addressing the underlying causes, and investing in prevention and treatment programs, it is possible to maximize children's health and wellbeing on a global scale. This narrative review will focus on the impact of childhood malnutrition on lung development, the consequent respiratory disease, and what actions can be taken to reduce the burden of malnutrition on lung health.
- 17 May 2024
- Published by Springer Nature in Pulmonary Therapy
- Vol. 10 (2) , 155-170
Open AccessThe Impact of Malnutrition on the Developing Lung and Long-Term Lung Health: A Narrative Review of Global Literature
Worldwide, over 2 billion children under the age of 5 experience stunting, wasting, or are underweight. Malnutrition contributes to 45% of all deaths in this age group (approximately 3.1 million deaths) [1]. Poverty, food insecurity, suboptimal feeding practices, climate change, and conflict are all contributing factors. Malnutrition causes significant respiratory problems, including increased risk of respiratory infections, impaired lung function, and increased risk of subsequent adult respiratory disease, including asthma, COPD, and lung cancer. Childhood malnutrition not only has serious consequences for children's health but it also has numerous consequences on wellbeing and educational attainment. Childhood malnutrition is a complex and multifaceted problem. However, by understanding and addressing the underlying causes, and investing in prevention and treatment programs, it is possible to maximize children's health and wellbeing on a global scale. This narrative review will focus on the impact of childhood malnutrition on lung development, the consequent respiratory disease, and what actions can be taken to reduce the burden of malnutrition on lung health.
- Open Access
- 7 December 2021
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 17 (4) , 210110
Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?
It is uncertain whether immunoprophylaxis against RSV protects preterm babies with BPD against future respiratory problems. It is biologically plausible that it does, at least in some infants.https://bit.ly/3ikzwZD
- 7 December 2021
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 17 (4) , 210110
Open AccessPalivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?
It is uncertain whether immunoprophylaxis against RSV protects preterm babies with BPD against future respiratory problems. It is biologically plausible that it does, at least in some infants.https://bit.ly/3ikzwZD
- 1 June 2021
- Published by European Respiratory Society (ERS)
Introduction
- 1 June 2015
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 16 (3) , 162-164
Potentiators for cystic fibrosis – targeting the underlying molecular defect
- 1 June 2015
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 16 (3) , 162-164
Potentiators for cystic fibrosis – targeting the underlying molecular defect
- 24 February 2014
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 2
Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
- 24 February 2014
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 2
Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis